GenFleet Therapeutics Seeks HK$467 Million via H-Share Placement; Shares Up 11%

MT Newswires Live07-15

GenFleet Therapeutics (Shanghai) (HKG:2595) is seeking to raise net proceeds of about HK$466.9 million through the placement of 13.6 million new H-shares, according to a Hong Kong bourse filing on Wednesday.

The company is offering the shares at HK$34.69 each, representing a 9.71% discount to the last closing price.

The net proceeds will primarily be used to advance the clinical development of its RAS inhibitor pipeline, enhance its research and development platforms, and for working capital and general corporate purposes.

The new shares represent about 3.67% of the company's existing issued share capital and about 3.54% of its enlarged share capital after the placement.

Shares of the biopharmaceutical company were up over 11% in Wednesday afternoon trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment